Free Newsletter
IV Relenza saves U.K. woman from H1N1 flu
Free newsletter via e-mail
Tools
Mainlining GlaxoSmithKline's Relenza could end up as the swine-flu treatment of last resort. British doctors saved the life of a woman with severe H1N1 flu, using an unapproved IV form of the Glaxo antiviral. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
